Search Results - against

31 Results Sort By:
Monoclonal Antibody Against Human Alpha-5 Integrin that Does Not Disrupt Adhesive Function
This technology includes a rat monoclonal antibody termed mAb11 was generated against the human alpha-5 integrin subunit and can provide immunological characterizations without disrupting integrin adhesive function. It permits characterization of its localization even if the receptor is bound to its fibronectin ligand. The antibody is commercially available...
Published: 12/26/2024   |   Inventor(s): Steven Akiyama, Susan Yamada, Kenneth Yamada
Keywords(s): Against, Alpha-5, ANTIBODY, DISRUPT, DOES, FUNCTION, Human, INTEGRIN, monoclonal, That, WIXXXX, XAXXXX
Category(s): Application > Research Materials, ResearchProducts > Antibodies, TherapeuticArea > Immunology
Novel VAR2CSA Immunogens and Methods of Use Thereof
The invention provides immunogen polypeptides comprising fragments of VAR2CSA protein expressed by P. falciparum as potential second-generation placental malaria vaccine candidates. VAR2CSA is the leading antigen target for a placental malaria vaccine, where associated antibody titers are correlated with protection. Aspects of the inventive immunogen...
Published: 10/28/2024   |   Inventor(s): Rui Ma, Niraj Tolia
Keywords(s): Against, CANCER, COMPOSITION, COMPRISING, Diagnostics, IMMUNOGENS, Malaria, Matter, Placental, PROTECT, proteins, That, therapeutics, Used
Category(s): Collaboration Sought > Collaboration
Conformation Dependent Anti-major Outer Membrane Protein (MOMP) Monoclonal Antibody BD5
A murine hybridoma expressing mAb BD3 was found to react with a conformationally dependent epitope on the chlamydial Major Outer Membrane Protein (MOMP), a primary target of neutralizing antibodies and vaccine development. The BD3 neutralized the in vitro infectivity of C. trachomatis serovars B, Ba, D, E, L2. It is useful for verifying the correct...
Published: 10/28/2024   |   Inventor(s): Harlan Caldwell
Keywords(s): Against, ANTIBODY, Anti-major, B, ba, BD5, Chlamydia, CONFORMATION, Correct, D, Dependent, e, Hybridoma, L2, Listed LPM Thalhammer-Reyero as of 4/15/2015, Mab, MEMBRANE, MOMP, monoclonal, OUTER, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Protein, RM, SEROVARS, TRACHOMATIS, USEFUL, vaccines, Verifying, WIXXXX
Category(s): Collaboration Sought > Licensing, Application > Research Materials
Hybridoma Cell Line H9.2B8 Producing Monoclonal Anti-mouse CD51 (Vitronectin receptor, alpha chain) Antibody
A hybridoma cell line producing a monoclonal hamster antibody specific to mouse CD51 (vitronectin receptor, alpha chain) (clone H9.2B8) as described in J Exp Med. 1989 Jun 1;169(6):2173-90 and developed by the laboratory of Dr. Ethan Shevach at the National Institute of Allergy and Infectious Diseases.
Published: 10/28/2024   |   Inventor(s): Ethan Shevach
Keywords(s): AC5XXX, Against, ALPHA, antibodies, ANTIGENS, Cell, Chain, Clone:, H9.2B8, Hamster, Hybridoma, Listed LPM Nguyen-Antczak as of 4/15/2015, Mab, Mouse, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, RECEPTOR, RM, Surface, Vitronectin, WIXXXX
Category(s): Collaboration Sought > Licensing, Application > Research Materials
Chlamydial Vaccine Technologies
The National Institute of Allergy and Infectious Diseases has invented three chlamydial vaccine technologies, which have shown promising preclinical efficacy. Chlamydia trachomatis infection is the most common sexually transmitted bacterial infection. If left untreated, chlamydia infection can lead to pelvic inflammatory disease and infertility. Chlamydia...
Published: 10/28/2024   |   Inventor(s): Laszlo Kari, Deborah Crane, Harlan Caldwell
Keywords(s): Against, Attenuated, -Attenuated, Bacterial strains, Blinding, Chlamydia, DA3XXX, DC4XXX, DCXXXX, DD1XXX, DDXXXX, DISEASES, Human, Immunogenic, Listed LPM Stansberry as of 4/15/2015, Live, Model, MULTIPLE, NON, Patent Category - Biotechnology, Plasmid-deficient, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, primate, Protective, RM, SAFE, Sexually, Strain, Trachoma, TRACHOMATIS, Transmitted, UBXXXX, Vaccine, VJXXXX, WIXXXX, WNXXXX
Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Research Materials, TherapeuticArea > Rare / Neglected Diseases, Application > Diagnostics
Broadly Neutralizing Antibodies Against HIV-1 Directed to the CD4 Binding Site of HIV Envelope Protein
Inhibiting the ability of HIV-1, the virus that causes AIDS, to infect cells is one approach to both prevention and treatment of HIV. Scientists at the NIAID Vaccine Research Center have isolated and characterized neutralizing antibodies (VRC01, 02, 03, and 07) that bind to the CD4 binding site of HIV-1 envelope glycoprotein gp120. These human monoclonal...
Published: 10/28/2024   |   Inventor(s): Richard Wyatt, Xueling Wu, Yuxing Li, Carl-Magnus Hogerkorp, Mario Roederer, Zhi-yong Yang, Gary Nabel, Peter Kwong, Tongqing Zhou, Mark Connors, Gilad Ofek, Yongping Yang, Jiang Zhu, Lawrence Shapiro, William Schief, Rebecca Rudicell, Ivelin Georgiev, Young Do Kwon, Baoshan Zhang, Gwo-yu Chauang, Wei Shi, Gwo-Yu Chuang, John Mascola
Keywords(s): Against, antibodies, Antibodies., ANTIBODY, Antibody-based, B-Cells, Broadly, Chain, Constructs, CREATION, DA4AXX, DB4AXX, DC5AXX, DD2XXX, Epitope-Specific, Expressing, FUNCTION, Further, GENERAL, GLYCOPROTEIN, gp120, HIV, HIV-1, Identity, Immunoadesion, Immunoadhesin, Isolation, Listed LPM Thalhammer-Reyero as of 4/15/2015, MODE, Modifications, monoclonal, Monoco, Neutizing, Neutralization, Neutralizing, Novel, Patent Category - Biotechnology, Post LPM Assignment Set 20150420, Pre LPM working set 20150418, Probes, Single, Specific, VRC03, VRC03Isolation
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Diagnostics, Application > Research Materials
Human and Veterinary Cancer Therapeutic Agent Utilizing Anthrax Toxin-Based Technology
Due to the disorganized nature of blood vessels that run through tumors, chemotherapeutic agents often fail to penetrate tumors and kill cancer cells at the tumor’s center. This can lead to ineffective chemotherapeutic treatments, because tumors can quickly grow back if the entire tumor is not destroyed. NIH researchers have developed a therapeutic...
Published: 10/28/2024   |   Inventor(s): Stephen Leppla, Thomas Bugge, Diane Peters, Jie Liu, Alexander Wein, Kuang-Hua Chen, Shihui Liu
Keywords(s): Against, Anthrax, CMG2, EFFICACY, FELINE, FELINE Leukemia, Having, IC2-PA, Improved, Leppla, MARKER, SOLID, Specificity, Strong, Targeting, toxin, tumor, Types, VARIANTS, VASCULATURE, VETERINARY
Category(s): Collaboration Sought > Collaboration
Chimeric Antibodies Against Hepatitis B e-Antigen
The invention relates to recombinant chimeric rabbit/human monoclonal antibody fragments (Fabs) against hepatitis B Virus e-antigen (HBeAg), notably Fab me6. Viral hepatitis is the seventh leading cause of death worldwide. Hepatitis B core antigen (HBcAg) forms an icosahedral structure containing the viral genome. Both the HBcAg and the HBeAg of interest...
Published: 12/27/2024   |   Inventor(s): Norman Watts, Alasdair Steven, Paul Wingfield
Keywords(s): Against, antibodies, APPLICATIONS, assay, B, CHARACTERIZATION, chimeric, Chimic, DB4XXX, E-antigen, FAB, Hepalitis, Hepatitis, Potential, Rabbit/human, Their, THERAPY, VLXXXX, WJXXXX, XAXXXX
Category(s): TherapeuticArea > Immunology, Application > Therapeutics, TherapeuticArea > Infectious Disease, ResearchProducts > Antibodies
AMA1-RON2 Complex-Based Vaccine Against Malaria
This technology relates to a malaria vaccine composed of a protein complex of Apical Membrane Antigen (AMA1) and rhoptry neck protein 2 (RON2) with an adjuvant. AMA1 is a crucial component of the Plasmodium invasion machinery and is a leading candidate for antimalarial vaccine development. AMA1-based vaccines have shown ability to block red cell invasion...
Published: 10/28/2024   |   Inventor(s): Louis Miller, Prakash Srinivasan
Keywords(s): Against, AMAI-RON2, CHALLENGE, COMPLEX, DC2XXX, Lethal, PLASMODIUM, Protection, PROVIDES, VACCINATION
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Infectious Disease, Application > Vaccines
Viral Like Particles Based Chikungunya Vaccines
Chikungunya virus (CHIKV) is mosquito-borne alphavirus endemic in Africa, India, and Southeast Asia. In 2013 CHIKV infection has also emerged in the Caribbean and a pandemic of CHIKV has re-emerged in the Philippines following Typhoon Haiyan. Currently, there is no vaccine available for the prevention of CHIKV infection and no specific therapy exists...
Published: 10/28/2024   |   Inventor(s): Wataru Akahata, Srinivas Rao, Gary Nabel
Keywords(s): Against, ALPHA, ALPHAVIRUS, CAPSID, Chikungunya, CHIKV, DC5BXX, Development, DNA vaccine, E1, E1-E2, E2, Envelope, Generation, Method, MODIFICATION, Modifications, PARTICLES, Patent Category - Biotechnology, PLASMID, PREVENTIVE, production, Protein, proteins, Vaccine, VBXXXX, viral, virus, VIRUS-LIKE, VLPs, VLXXXX, XHXXXX
Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Infectious Disease, Application > Vaccines, Application > Diagnostics, ResearchProducts > Research Equipment
1 2 3 4